ANEB Stock Overview
A clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Anebulo Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.08 |
52 Week High | US$3.61 |
52 Week Low | US$1.62 |
Beta | -1.02 |
11 Month Change | 54.00% |
3 Month Change | 14.93% |
1 Year Change | -6.10% |
33 Year Change | -55.04% |
5 Year Change | n/a |
Change since IPO | -56.62% |
Recent News & Updates
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 22Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Recent updates
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 22Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?
Jul 03Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 07We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth
Nov 19Anebulo Pharmaceuticals to launch private investment in public equity financing
Sep 26Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
Sep 09Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 28Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 15Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Nov 04Anebulo Pharmaceuticals reports FQ3 results
Jun 21Shareholder Returns
ANEB | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 48.1% | -0.1% | 2.6% |
1Y | -6.1% | 21.2% | 30.5% |
Return vs Industry: ANEB underperformed the US Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: ANEB underperformed the US Market which returned 30.5% over the past year.
Price Volatility
ANEB volatility | |
---|---|
ANEB Average Weekly Movement | 18.3% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANEB's share price has been volatile over the past 3 months.
Volatility Over Time: ANEB's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 2 | Richie Cunningham | www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company’s lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Fundamentals Summary
ANEB fundamental statistics | |
---|---|
Market cap | US$53.94m |
Earnings (TTM) | -US$9.35m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.5x
P/E RatioIs ANEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ANEB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$9.35m |
Earnings | -US$9.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.36 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ANEB perform over the long term?
See historical performance and comparison